A phase 1b/2 trial shows that #allogeneic #NKcell therapy plus #chemotherapy is safe in #AdvancedPancreaticCancer, with 31.6% response; #MultiomicProfiling reveals NK/T‑cell subsets linked to outcomes, offering novel immune insights.
#OpenAccess in STTT: doi.org/10.1038/s413...